Pascal Biosciences Inc., a drug discovery and development company, announced recently that the company has executed an exclusive, worldwide license option agreement with STC.UNM, The University of New Mexico’s technology-transfer and economic-development
Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release
Structure, Function, and Inhibition of Chemokines
Recognition and functional activation of the human IgA receptor (FcαRI) by C-reactive protein
Sol–Gel‐Based Advanced Porous Silica Materials for Biomedical Applications - Lei - 2020 - Advanced Functional Materials - Wiley Online Library
Microscopy and Image Analysis - McNamara - 2017 - Current Protocols in Human Genetics - Wiley Online Library
Frontiers Engineering an Antibody V Gene-Selective Vaccine
Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b)
Recognition and functional activation of the human IgA receptor (FcαRI) by C-reactive protein
Recognition and functional activation of the human IgA receptor (FcαRI) by C-reactive protein
Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b)
Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release
Pascal Biosciences acquires technology to treat leukemia from The University of New Mexico: UNM Newsroom
Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release
Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release
Topics Archives - Vista Partners LLCVista Partners LLC